Article Text

Download PDFPDF
Renin-angiotensin system modulating treatments in the management of cardiovascular disease
  1. LARS RYDÉN, Guest editor
  1. Department of Cardiology
  2. Karolinska Hospital
  3. Stockholm
  4. Sweden
  5. email:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

As demand grows for more effective and evidence based management of cardiovascular disease, treatments which modify the renin-angiotensin system (RAS) have become a major focus for research. As a consequence, RAS modulating agents such as angiotensin converting enzyme (ACE) inhibitors and angiotensin II type 1 (AT1) receptor blockers have attracted much scientific interest.

It is no surprise then that the current evidence for RAS modulating treatment—and the possible directions for the future—became the subject of a major international two day meeting, held in November 1999. While looking to the future, the meeting provided a valuable forum for assessing the current standard of cardiovascular evidence and practice, and reviewing its clinical implications.

The meeting explored the wealth …

View Full Text